WCLC Interview | Dr. Baohui Han: Discussion and Prospects of Hot Topics in Targeted Therapy of Lung Cancer

WCLC Interview | Dr. Baohui Han: Discussion and Prospects of Hot Topics in Targeted Therapy of Lung Cancer

The 2023 World Conference on Lung Cancer (WCLC), held from September 9th to 12th at the Singapore, provided a platform for oncology experts to delve into cutting-edge developments. The “Oncology Frontier” team reports on-the-spot international cutting-edge developments and witnesses the progress of China's anti-cancer cause on the international stage. Renowned oncologist Dr. Baohui Han, from the Shanghai Chest Hospital, delivered a significant address at the conference. In an exclusive interview with “Oncology Frontier”, Dr. Han shared profound insights into the latest breakthroughs and contemplations on hot topics in targeted therapy for lung cancer.
Dr. Niels Van de Donk: Navigating the Horizon of CAR-T Treatment for RRMM

Dr. Niels Van de Donk: Navigating the Horizon of CAR-T Treatment for RRMM

Editor's Note: In this captivating interview, Dr. Niels Van de Donk offers an extensive exploration of the recent advancements and future prospects in Chimeric Antigen Receptor T-cell (CAR-T) therapy for relapsed/refractory multiple myeloma (RRMM). Dr. Donk's insights, ranging from the dynamic landscape of CAR-T targets to pivotal studies like MAJESTEC-1, provide a comprehensive overview of the current status, challenges, and promising directions in the ever-evolving field of RRMM treatment.01 Oncology Frontier: Unpacking the Current Progress in CAR-T Targets for RRMM
IDWeek Commentary | Dr. Mei Zeng: Racing Against Time! Developing a Predictive Model for Early Identification of Severe Infections in Newborns

IDWeek Commentary | Dr. Mei Zeng: Racing Against Time! Developing a Predictive Model for Early Identification of Severe Infections in Newborns

Half of all global child deaths under the age of 5 are caused by infections, and half of all sepsis patients worldwide are children, especially newborns. These alarming statistics highlight the significant challenge of infection treatment in pediatric clinical practice. At the recent IDWeek 2023 in the United States, a predictive model for severe infection in infants under 90 days of age, based on clinical data and inflammatory biomarkers, was reported. This predictive model may aid in the early identification of newborns at high risk of severe infection, allowing timely clinical intervention to reduce the risk of disease progression. Dr. Mei Zeng from the Children's Hospital of Fudan University/National Children's Medical Center provides an introduction and commentary on this research.
Dr. Chao Wu: Current State and Prospects of Clinical Cure for Hepatitis B

Dr. Chao Wu: Current State and Prospects of Clinical Cure for Hepatitis B

Clinical cure of hepatitis B has been a hot topic in the field of viral hepatitis, and the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the 2023 EASL Congress unveiled numerous advancements in new drug research. Dr. Chao Wu and his team from the Department of Infectious Diseases at the Affiliated Drum Tower Hospital of Nanjing Medical University have been engaged in both clinical and basic research on viral hepatitis. In the 2023 EASL Congress, their team contributed 14 research findings, with three of them receiving the Young Investigator Awards. Hepatology Digest invited Dr. Chao Wu to discuss the current state of clinical cure for hepatitis B and analyze future prospects, as well as his thoughts on the overall development of liver diseases.